ウイルス性結膜炎パイプライン治療薬の世界市場:産業分析、パイプライン、特許分析、市場予測

◆英語タイトル:Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
◆商品コード:TMR607120
◆発行会社(調査会社):Transparency Market Research
◆発行日:2016年6月14日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥660,630見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥1,002,630見積依頼/購入/質問フォーム
Corporate LicenseUSD11,795 ⇒換算¥1,344,630見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

This report analyzes the current and future prospects of the viral conjunctivitis pipeline drugs market across major countries. Viral conjunctivitis is a highly contagious disease; however, not a single drug has been approved by the U.S. FDA to treat it. Hence, demand for these drugs for viral conjunctivitis is likely to increase after their expected launch.The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each drug for the period from expected launch to 2023, considering the macro and micro environmental factors. Growth rates for each drug within the market have been determined after a thorough analysis of current scenario, demographics, epidemiological study, future trends, competition with other pipeline drugs, and regulatory requirements.
The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on the drug and geographic analysis. Based on pipeline drug, the market has been segmented into FST-100 and APD-209. Market size estimations involved in-depth study of both the drugs and product information. Additionally, market related factors such as product innovation, number of viral conjunctivitis patients in various countries, and expected launch date were taken into consideration while estimating the market size. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from expected launch to 2023.
Based on geography, the market has been analyzed for major countries: the U.S., the U.K., Germany, Australia, Japan, and Brazil. The market forecast for each of these countries has been provided for the period from expected launch in the country to 2023, along with their respective CAGRs for the forecast period from expected launch to 2023. The countries are selected based on ongoing clinical trial for FST-100 and APD-209.
A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities have been provided in the market overview section. This section of the report also provides epidemiological data and patent analysis of pipeline drugs, with a thorough analysis of the overall competitive scenario in the viral conjunctivitis pipeline drugs market.
A list of recommendations has been provided for new entrants to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The viral conjunctivitis pipeline drugs market is highly consolidated. Major companies profiled in this market report are Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.
The viral conjunctivitis pipeline drugs market has been segmented as follows:
• Viral Conjunctivitis Pipeline Drugs Market, by Drug
o FST-100
o APD-209
• Viral Conjunctivitis Pipeline Drugs Market, by Country
o U.S.
o U.K.
o Germany
o Australia
o Japan
o Brazil

【レポートの目次】

1. Preface
1.1. Report Description
1.2. Research Methodology
1.3. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market – Industry Analysis
3.1. Introduction
3.1.1. Sign and Symptoms
3.1.2. Diagnosis
3.1.3. Management
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Large Unmet Needs
3.2.1.2. Strong Pipeline
3.2.2. Restraints
3.2.2.1. Low diagnosis rate
3.2.2.2. Self-Limiting Condition
3.2.3. Opportunity
3.2.3.1. Investment in Rigorous R&D Activities
3.2.3.2. Strengthen Commercialization Activities
3.3. Epidemiology
3.4. Patent Analysis of Pipeline Drugs

4. Market Segmentation – By Pipeline Drug
4.1. Introduction
4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation – By Country
5.1. Introduction
5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)
5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn)
5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn)
5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn)

6. Recommendations

7. Company Profiles
7.1. Adenovir Pharma AB
7.2. Allergan plc
7.3. NanoViricides, Inc.
7.4. Shire plc
7.5. NovaBay Pharmaceuticals, Inc.
7.6. Novartis AG
7.7. Panoptes Pharma GES.M.B.H.
7.8. NicOx S.A.

List of Figures

FIG. 1 Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
FIG. 13 NanoViricides, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 14 Shire plc, Financial Overview: (US$ Mn), 2013–2015
FIG. 15 NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 16 Novartis AG, Financial Overview: (US$ Mn), 2013–2015
FIG. 17 NicOx S.A., Financial Overview: (US$ Mn), 2013–2015

List of Tables

TABLE 1 Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
TABLE 2 Viral Conjunctivitis: Management
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023



【レポートのキーワード】

ウイルス性結膜炎パイプライン治療薬

★調査レポート[ウイルス性結膜炎パイプライン治療薬の世界市場:産業分析、パイプライン、特許分析、市場予測]販売に関する免責事項
★調査レポート[ウイルス性結膜炎パイプライン治療薬の世界市場:産業分析、パイプライン、特許分析、市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆